Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Revolutions Medical Corp. (RMCP.OB) is “One to Watch”

Revolutions Medical Corp. focuses on developing and manufacturing safety-engineered medical devices as well as software applications related to the healthcare field. Its current products include the RevVac Safety Syringe and the RevColorTM, RevDisplayTM and Rev3DTM software applications, all of which are fully-compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS).

The RevVac Safety Syringe uses patented technology to draw the needle into the syringe chamber after use for safety. The design of this syringe prevents accidental needle stick injuries. The RevVac Safety Syringe also prevents reuse of the syringe, decreasing the spread of blood borne diseases. Additionally, this safety syringe allows for one-handed use, a great benefit to health care practitioners and medical personnel as there are no clamps, sheaths, or other complex safety features that require use of both hands.

The world market for safety-engineered medical devices, such as the RevVac Safety Syringe, exceeds $1 billion in annual sales and is forecasted to maintain a 20% annual growth rate in the near term. Furthermore, Revolutions Medical’s software solutions and proprietary tools enhance the physician’s diagnostic confidence in an industry that is growing at 10% – 15% (more than 25 million procedures) per year with a worldwide market potential for these tools that exceeds $3.5 billion.

Earlier this month, Revolutions Medical was featured in an interview by Wall Street Reporter (NYSEMKT:WSR) Senior Analyst Juan Costello. The interview provides an overview of the Company, its technology and recent company achievements. Mr. Wheet also talked about the Company’s management team and its transition from strictly R&D to sales. The full interview can be heard at

Also this month, Revolutions Medical announced it has secured a 5-year contract to produce five million syringes per month of its RevVac 1ml fixed needle safety syringe, with the option of increasing production to 20 million syringes per month as demand increases. The manufacturer contracted currently ships medical products throughout the world and is compliant with all major international standards including FDA, CE Mark and Health Canada, as well as those required in Japan, China and India.

“The selection of this manufacturer in China, with its expert capabilities, provides Revolutions Medical with the ability to deliver the highest quality and cost effective product to the marketplace. With the strong performance history of this factory, we can be assured of meeting the high demand for the Company’s proprietary auto retractable vacuum safety syringes,” stated Rich Theriault, President of Strategic Product Development (SPD) and consultant to Revolutions Medical.

“Rich Theriault has extensive years of experience working with global manufacturing and will be managing this effort. His knowledge and expertise for delivering many quality products into the medical device marketplace is vast. It is important for Revolutions Medical to continue its extensive research and development projects as it transitions into sales during second quarter of 2011,” added Ron Wheet, CEO, Revolutions Medical Corporation.

As of last report, the company is still on schedule to manufacture and produce all of its other RevVac syringe sizes and its RevLok interchangeable needle designs later this year. Revolutions Medical is also working on its new prefilled vacuum safety syringe technology and should have designs completed this quarter.

Please see disclaimer on QualityStocks website: